NWS vs STRO · rev $9.03B vs rev $62.0M
NWS (NWS) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
NWS (NWS) common stock.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported NWS revenue for 2026-06-30 was $9.03B. Net income was $573.0M. Revenue was up 6.8% from 2025-06-30 to 2026-06-30. NWS currently screens at market cap $0.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
NWS currently screens at market cap $0. STRO currently screens at market cap $470.8M.
Not investment advice. Open the NWS and STRO stock pages for the full models.
Not investment advice.